Bone Marrow Derived Dendritic Cells are More Suitable Than Dendritic Cell Line DC2.4 to Study Tumor-Mediated Suppression of DC Maturation Through STAT3 Hyperactivation

被引:15
作者
Alshamsan, Aws [1 ]
Hamdy, Samar [1 ]
Das, Saswati [1 ]
Lavasanifar, Afsaneh [1 ]
Samuel, John [1 ]
El-Kadi, Ayman O. S. [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Dent Pharm Ctr 4132, Edmonton, AB T6G 2N8, Canada
来源
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES | 2010年 / 13卷 / 01期
关键词
CANCER; DIFFERENTIATION; TRANSDUCERS; INHIBITION; ACTIVATION;
D O I
10.18433/J37598
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. Tumors can escape immune eradication by harnessing dendritic cell (DC) maturation. However, DC types used as in vitro models to study tumor-mediated immunosuppression possess fundamental variability that could influence research outcomes. Therefore, we assessed the behavior of two distinct murine DC models upon exposure to tumor-conditioned medium of B16.F10 melanoma (B16-CM). Methods. Using primary bone-marrow derived dendritic cells (BMDCs) or immortalized DC2.4 cell line, we evaluated the level of signal transducer and activator of transcription 3 (STAT3) phosphorylation by Western blot as a molecular parameter. We also examined the surface expression of co-stimulatory molecules on DCs by flow cytometry as a phenotypic parameter. Results. Our results revealed critical discrepancies between the two models in response to tumor-conditioned medium. While conditioned medium was able to induce STAT3 phosphorylation in BMDCs, it did not significantly induce STAT3 phosphorylation in DC2.4 cell line. Moreover, only in BMDCs, the expression of CD86 and CD40 was remarkably downregulated by B16-CM and was not totally recovered after LPS stimulation. In contrast, DC2.4 cells did not show any signs of harnessed maturation upon exposure to B16-CM. Conclusions. In order to study the effect of tumor-mediated immunosuppression on DC maturation in vitro via tumor-induction of STAT3 activation, primary BMDCs are more reliable as a model than DC2.4.
引用
收藏
页码:21 / 26
页数:6
相关论文
共 10 条
  • [1] Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation
    Bharadwaj, Uddalak
    Li, Min
    Zhang, Rongxin
    Chen, Changyi
    Yao, Qizhi
    [J]. CANCER RESEARCH, 2007, 67 (11) : 5479 - 5488
  • [2] A critical role for stat3 signaling in immune tolerance
    Cheng, FD
    Wang, HW
    Cuenca, A
    Huang, M
    Ghansah, T
    Brayer, J
    Kerr, WG
    Takeda, K
    Akira, S
    Schoenberger, SP
    Yu, H
    Jove, R
    Sotomayor, EM
    [J]. IMMUNITY, 2003, 19 (03) : 425 - 436
  • [3] Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer
    Haura, EB
    Turkson, J
    Jove, R
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (06): : 315 - 324
  • [4] An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow
    Lutz, MB
    Kukutsch, N
    Ogilvie, ALJ
    Rössner, S
    Koch, F
    Romani, N
    Schuler, G
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1999, 223 (01) : 77 - 92
  • [5] Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-activated kinase 2/signal transducers and activators of transcription 3 pathway
    Nefedova, Y
    Nagaraj, S
    Rosenbauer, A
    Muro-Cacho, C
    Sebti, SM
    Gabrilovich, DI
    [J]. CANCER RESEARCH, 2005, 65 (20) : 9525 - 9535
  • [6] IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33(+) myeloma cells
    Shamsasenjan, Karim
    Otsuyama, Ken-ichiro
    Abroun, Saeid
    Iqbal, Mohd S.
    Mahmoud, Maged S.
    Asaoku, Hideki
    Kawano, Michio M.
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (03) : 310 - 318
  • [7] Shen ZH, 1997, J IMMUNOL, V158, P2723
  • [8] Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation
    Sombroek, CC
    Stam, AGM
    Masterson, AJ
    Lougheed, SM
    Schakel, MJAG
    Meijer, CJLM
    Pinedo, HM
    van den Eertwegh, AJM
    Scheper, RJ
    de Gruijl, TD
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (09) : 4333 - 4343
  • [9] Yang AS, 2003, CANCER RES, V63, P2150
  • [10] The stats of cancer - New molecular targets come of age
    Yu, H
    Jove, R
    [J]. NATURE REVIEWS CANCER, 2004, 4 (02) : 97 - 105